Compare Pfizer Inc (PFE) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Invesco S&P 500 Momentum ETF — how do they compare? Pfizer Inc trades at $27.83 (market cap $159.59B), while Invesco S&P 500 Momentum ETF trades at $152 (market cap $23.47B). The key difference: Pfizer Inc is far larger — about 6.8× Invesco S&P 500 Momentum ETF's market cap, and Pfizer Inc pays a 6.14% dividend while Invesco S&P 500 Momentum ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Invesco S&P 500 Momentum ETF for 54 Days on average.
| PFE | SPMO | |
|---|---|---|
Market Cap | $159.59B | $23.47B |
Volume | 30,937,010 | 2,035,258 |
Sector | Health | Broad Market / Factor |
52-Week High | $29.02 | $161.66 |
52-Week Low | $23.67 | $107.84 |
Typical Hold Time | 158 Days | 54 Days |
Enterprise Value | $211.09B | — |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
SPMO trades at $153.00 with minimal daily movement (+0.01%). The ETF maintains a bullish technical stance with strong moving average signals, though oscillators show neutral momentum. Recent portfolio rebalancing added 54 stocks including Apple and Merck, while removing Nvidia. Institutional interest grew with Envestnet Asset Management increasing its stake by 9.5% in Q2 2026.
SPMO offers concentrated exposure to S&P 500 momentum leaders with historical outperformance. Key risks include sector concentration in technology and semiconductors, plus higher volatility than the broader market. The fund's momentum strategy faces challenges during market rotations but maintains structural advantages for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
